TABLE 1.
IHC Scores for HER2 in Primary Breast Carcinomas According to Clinicopathologic Variables
| Variable | No. Patients (n = 91) | Primary HER2 = 0 | Primary HER2 = 1 + | Primary HER2 = 2 + | Primary HER2 = 3 + | |
|---|---|---|---|---|---|---|
| Age (y) | P = 0.16 | |||||
| 20–35 | 7 | 3 | 3 | 1 | 0 | |
| 36–50 | 49 | 32 | 5 | 3 | 9 | |
| 51–70 | 34 | 17 | 5 | 1 | 11 | |
| >70 | 1 | 1 | 0 | 0 | 0 | |
| Race | P = 0.56 | |||||
| White | 64 | 36 | 10 | 2 | 16 | |
| Black | 8 | 5 | 0 | 1 | 2 | |
| Hispanic | 14 | 8 | 2 | 2 | 2 | |
| Other | 5 | 4 | 1 | 0 | 0 | |
| Menopausal Status | P = 0.53 | |||||
| Pre | 48 | 29 | 8 | 4 | 7 | |
| Post | 39 | 21 | 5 | 1 | 12 | |
| Unknown | 4 | 3 | 0 | 0 | 1 | |
| Tumor Size (cm) | P = 0.85 | |||||
| ≤1 | 6 | 4 | 1 | 0 | 1 | |
| 1.1–2.0 | 18 | 11 | 3 | 0 | 4 | |
| 2.1–3.0 | 28 | 18 | 3 | 1 | 6 | |
| 3.1–4.0 | 19 | 9 | 3 | 2 | 5 | |
| 4.1–5.0 | 8 | 3 | 1 | 1 | 3 | |
| >5.0 | 7 | 3 | 2 | 1 | 1 | |
| Unknown | 5 | 5 | 0 | 0 | 0 | |
| Tumor Grade | P = 0.11 | |||||
| 1 | 6 | 5 | 1 | 0 | 0 | |
| 2 | 39 | 25 | 2 | 4 | 8 | |
| 3 | 46 | 23 | 10 | 1 | 12 | |
| No. Positive Lymph | P = 0.87 | |||||
| Nodes | ||||||
| 1–3 | 63 | 38 | 8 | 3 | 14 | |
| 4–9 | 19 | 11 | 3 | 1 | 4 | |
| >9 | 9 | 4 | 2 | 1 | 2 | |
| Lymphovascular | P = 0.33 | |||||
| Invasion | ||||||
| Present | 38 | 20 | 8 | 3 | 7 | |
| Absent | 53 | 33 | 5 | 2 | 13 | |
| ER | P = 0.011 | |||||
| Positive | 56 | 36 | 10 | 4 | 6 | |
| Negative | 35 | 17 | 3 | 1 | 14 | |
| PR* | P = 0.025 | |||||
| Positive | 42 | 28 | 8 | 2 | 4 | |
| Negative | 47 | 24 | 4 | 3 | 16 |
*
Of the 91 patients, satisfactory IHC stains for PR were obtained in 89.
ER indicates estrogen receptor; IHC, immunohistochemical; PR, progesterone receptor.